Jaguar Health

Jaguar Health, Inc. is a commercial stage pharmaceuticals company, which engages in the development of gastrointestinal products. The firm focuses on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. It operates through the Human Health and Animal Health segments. The Human Health segment manufactures human products and the ongoing advertising of Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The Animal Health segment commercializes prescription and non-prescription products for companion and production animals. The company was founded by Lisa A. Conte on June 6, 2013 and is headquartered in San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Jaguar Health reports revenue growth and eyes cancer therapy market

Jaguar Health's Q1 2024 performance showed revenue growth and improved financial metrics. The company's strategic focus on cancer supportive care and rare diseases positions it for future growth. Challenges include trial result uncertainties and regulatory timelines, but opportunities exist in market expansion and new programs.

Jaguar Health reports revenue growth and promising clinical trial results

Jaguar Health's Q2 2024 earnings call showcases revenue growth, positive clinical trial outcomes, and strategic plans for product launches and FDA discussions. The company's focus on improving patient outcomes and expanding its product reach positions it for future success in the healthcare market.

Jaguar Health reports revenue growth and advances in cancer care

Jaguar Health's Q3 performance reflects revenue growth, successful trial outcomes, and a focus on cancer patient care through innovative products.
While facing challenges in regulatory processes and financial metrics, the company is well-positioned to capitalize on opportunities in rare diseases and oncology.
Overall, Jaguar Health's strategic initiatives and commitment to addressing critical medical needs position it for potential growth and impact in the healthcare sector.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Jaguar Health, Inc. is a commercial stage pharmaceuticals company, which engages in the development of gastrointestinal products. It operates through the Human Health and Animal Health segments. The Human Health segment is involved in manufacturing human products and the ongoing advertising of Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The Animal Health segment includes commercializing prescription and non-prescription products for companion and production animals. The company was founded by Lisa A. Conte on June 6, 2013 and is headquartered in San Francisco, CA.

JAGX shares are once again on the move this week. Here's what you should know about the maker of the antidiarrheal treatment Mytesi.

JAGX Stock: 12 Things to Know About Fast-Moving Jaguar Health

JAGX stock is up on news that Jaguar Health just signed a royalty deal that will allow the company to pursue new FDA approvals. The post JAGX Stock: Why Jaguar Health Shares Are Surging 150% Today appeared first on InvestorPlace.

JAGX Stock: Why Jaguar Health Shares Are Surging 150% Today

BIOLASE

Senseonics Holdings

Tonix Pharmaceuticals Hld

This article is going to explain what penny stocks are and discuss four penny stocks under $1 to watch as small-cap stocks continue a hot streak this winter. First thing's first, what are penny stocks?

4 Hot Penny Stocks Trading Under $1 That Need To Be On Your Watchlist

No royalty payments due for 18-24 months Proceeds will be allocated to support regulatory activities associated with the Company's development pipeline, including funding the recently initiated pivotal clinical trial for crofelemer (Mytesi®) for cancer therapy-related diarrhea (CTD), for which patient enrollment is progressing SAN FRANCISCO, CA / ACCESSWIRE / December 23, 2020 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that the Company has signed an agreement (the "Agreement") with a secured lender (the "Lender") for a non-dilutive royalty financing transaction, pursuant to which Jaguar would sell to the Lender for an aggregate purchase price of $6 million (the "Royalty Purchase Price") a royalty interest entitling the Lender to receive 2.0x the Royalty Purchase Price of future royalties of Mytesi® (crofelemer) and lechlemer and certain up-front license fees and milestone payments from licensees and/or distributors as well as any interest, fees, and charges in accordance with the terms set forth in the Agreement (the "Royalty Repayment Amount"), and to pay interest on the Royalty Repayment Amount at the rate of ten percent per annum until the same is paid in full. Jaguar intends to use the proceeds to support regulatory activities associated with the Company's development pipeline, including funding continued patient enrollment for the pivotal Phase 3 trial of crofelemer (Mytesi) for prophylaxis of diarrhea in adult cancer patients receiving targeted therapy ("cancer therapy‑related diarrhea" (CTD)), which the Company's wholly owned subsidiary, Napo Pharmaceuticals, Inc. (Napo), initiated this past October.

Jaguar Health Signs Second Agreement for $6 Million Non-dilutive Financing Transaction Involving the Sale of Royalty Rights Related to Future Mytesi (Crofelemer) and Lechlemer Revenue Stream

All proposals approved Company not implementing a reverse split at this time Swiss Growth Forum hosting investor webinar Wednesday, December 23rd at 10:30 AM Eastern regarding appearance of new coronavirus strain underscoring urgency to seek European conditional approval for crofelemer for ‘long-hauler' syndrome gastrointestinal distress as strategy pursued in potential merger of Napo EU with the European Post Pandemic Recovery Equity special purpose acquisition company (SPAC) SAN FRANCISCO, CA / ACCESSWIRE / December 22, 2020 / Jaguar Health, Inc. (NASDAQ:JAGX) (''Jaguar'' or the ''Company'') today announced the voting results of Jaguar's December 9, 2020 Special Meeting of Stockholders (the "Special Meeting"), which, as previously announced, was adjourned until December 22, 2020. Two proposals were submitted to and approved by the stockholders of the Company at the Special Meeting.

Jaguar Health Reports Voting Results from Special Meeting of Stockholders & Announces December 23rd Investor Webinar

The stock price of Jaguar Health, Inc. (NASDAQ:JAGX) is trading at more than 50% today. This is why it happened.

JAGX Stock Price Increases Over 50%: Why It Happened

Jaguar Health (JAGX) is on the move Tuesday as shares of JAGX stock continue to rise and InvestorPlace has what investors need to know. The post Jaguar Health: 10 Things for JAGX Stock Investors to Know About the Pharmaceutical Company appeared first on InvestorPlace.

Jaguar Health: 10 Things for JAGX Stock Investors to Know About the Pharmaceutical Company

OncoCyte

Jaguar Health (NASDAQ: JAGX) shares are trading higher on Monday after the company announced its plans to develop and commercialize its Crofelemer. Jaguar Health is a commercial-stage pharmaceuticals company focused on developing novel, sustainably derived gastrointestinal products.

Why Jaguar Health And OncoCyte Are Trading Higher Today

Jaguar Health, Inc. (JAGX) CEO Lisa Conte on Q3 2020 Results - Earnings Call Transcript 

The following post is sponsored by Jaguar Health, Inc. It is for informational purposes only and not intended to be investing advice. With more than 30 years of ethnobotanical field research and ethnopharmacological compound analysis encompassing plant species and medical traditions from indigenous communities throughout the world's rainforest and tropical biomes, the management team at Jaguar Health (NASDAQ: JAGX) has garnered a unique reservoir of knowledge and expertise within the biotech industry.

Jaguar Health CEO And Lead Ethnobotanical Researcher Explain The Decades Of Research That Made It A Leader In Plant-Based Drug Treatment

The following post is sponsored by Jaguar Health, Inc. It is for informational purposes only and not intended to be investing advice. Next Tuesday, October 20th, Jaguar Health, Inc. (NASDAQ: JAGX) will hold a live virtual webinar intended for investors that will bring together experts in patient support, medical oncology and pharmaceutical research to discuss the current landscape of supportive care for cancer patients.

Jaguar Health CEO Discusses Upcoming Virtual Event Highlighting Long-Term Treatment Needs Of Cancer Patients

Brighthouse Financial

Second Sight Medical Products

RumbleON

Soleno Therapeutics

If you're wondering how markets are still surging in light of record-breaking coronavirus cases, our deep learning algorithms paired with Artificial Intelligence (“AI”) technology has you covered with the Top Shorts today.

Top Stocks To Short As Dow Passes 300 Points

Synchronoss

Scorpio Tankers

Venus Concept

Forget undervalued stocks, play these top-ranked stocks with rising P/E.

Bet on 4 Stocks With Rising P/E to Beat Market Blues

Jaguar Health's (JAGX) CEO Lisa Conte on Q1 2020 Results - Earnings Call Transcript

Jaguar Health, Inc. (JAGX) CEO Lisa Conte on Q4 2019 Results - Earnings Call Transcript

Jaguar Health Inc. said Monday evening it has regained compliance with all applicable Nasdaq Stock Market listing standards.

Jaguar Health Says It Has Regained Nasdaq Compliance

Jaguar Health shares spiked higher Tuesday morning after the company announced its subsidiary, Napo Pharmaceuticals, will receive preclinical services from the federal government to support the development of the drug lechlemer that treats cholera.

Jaguar Health Spikes 50% After Subsidiary Receives Preclinical Services From NIAID

News for Jaguar Health Stock (JAGX)